Zurich-Schlieren, May 26, 2020. Proteomedix, the Swiss cancer diagnostics company is pleased to announce the appointment of Dr Maurizio Ballerini, MD as VP Market Development EMEA and Dr Helene Peyro Saint-Paul, MD, as Medical Advisor effective June 1, 2020. These accomplished executives bring a wealth of industry expertise to the pioneering prostate diagnostic company.
Dr Ballerini is a diagnostics industry expert and brings more than 25 years of well-rounded international business experience in market development, scientific affairs, medical science liaison, marketing and sales to the company. Prior to joining Proteomedix, Dr Ballerini held various medical, commercial and country management positions with MDxHealth, GenProbe, Stryker, Randox Laboratories and Abbott. He received his MD in medicine and surgery from the Sapienza University of Rome, Italy.
I am delighted to welcome Maurizio to the Proteomedix executive team,” stated Helge Lubenow, Chief Executive Officer. “I am confident that his broad ranging acumen in the urology and uro-oncology field will play an instrumental role in enhancing and driving our commercial strategy for our lead product Proclarix and our pipeline of products dedicated to improve patient management in prostate cancer diagnostics. Maurizio’s contributions will build on our momentum during this pivotal phase in Proteomedix’ growth”.
Dr Helene Peyro Saint-Paul obtained her MD from the Toulouse Medical School, France, and specialized in neurology. She holds an Executive MBA (ESSEC, France). Over the last 25 years she has built a significant track record in international development, regulatory affairs, market access and launch of innovative drugs and in vitro diagnostics. Throughout her corporate leadership positions at Serono, Actelion, Ipsogen and QIAGEN, and her experience as a startup founder, Helene has also developed a solid expertise in corporate growth and strategic marketing.
We are very fortunate to be able to welcome Helene to the Proteomedix corporate advisor group,” stated Ralph Schiess, Chief Scientific Officer. “Her significant experience in in vitro diagnostic testing and oncology will enable us to further define and expand on our medical and clinical strategy for our lead product Proclarix and our pipeline products dedicated to improve patient management in prostate cancer.”
Proclarix® is CE marked, intended for in vitro diagnostic use and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient`s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer.
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score introduced to the market early 2020. Proteomedix is located in the Bio-Technopark of Schlieren, Switzerland. For more information, visit www.proteomedix.com
For further details, please contact:
Dr. Ralph Schiess, CSO